BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kenny HC, Abel ED. Heart Failure in Type 2 Diabetes Mellitus. Circ Res. 2019;124:121-141. [PMID: 30605420 DOI: 10.1161/circresaha.118.311371] [Cited by in Crossref: 148] [Cited by in F6Publishing: 65] [Article Influence: 49.3] [Reference Citation Analysis]
Number Citing Articles
1 Chen C, Huang Y, Zeng Y, Lu X, Dong G. Targeting the DPP-4-GLP-1 pathway improves exercise tolerance in heart failure patients: a systematic review and meta-analysis. BMC Cardiovasc Disord 2019;19:311. [PMID: 31870322 DOI: 10.1186/s12872-019-01275-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Passantino A, Rizzo C, Scrutinio D, Palazzuoli A. Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions. Heart Fail Rev 2021. [PMID: 34725782 DOI: 10.1007/s10741-021-10186-7] [Reference Citation Analysis]
3 Wang D, Yin Y, Wang S, Zhao T, Gong F, Zhao Y, Wang B, Huang Y, Cheng Z, Zhu G, Wang Z, Wang Y, Ren J, Liang G, Li X, Huang Z. FGF1ΔHBS prevents diabetic cardiomyopathy by maintaining mitochondrial homeostasis and reducing oxidative stress via AMPK/Nur77 suppression. Signal Transduct Target Ther 2021;6:133. [PMID: 33762571 DOI: 10.1038/s41392-021-00542-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hu S, Su X, Deng X, Wang Y. Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China. Front Pharmacol 2021;12:701446. [PMID: 34177604 DOI: 10.3389/fphar.2021.701446] [Reference Citation Analysis]
5 Chang X, Zhang T, Wang J, Liu Y, Yan P, Meng Q, Yin Y, Wang S. SIRT5-Related Desuccinylation Modification Contributes to Quercetin-Induced Protection against Heart Failure and High-Glucose-Prompted Cardiomyocytes Injured through Regulation of Mitochondrial Quality Surveillance. Oxid Med Cell Longev 2021;2021:5876841. [PMID: 34603599 DOI: 10.1155/2021/5876841] [Reference Citation Analysis]
6 Cai X, Zhu Q, Wu T, Zhu B, Aierken X, Ahmat A, Li N. Development and Validation of a Novel Model for Predicting the 5-Year Risk of Type 2 Diabetes in Patients with Hypertension: A Retrospective Cohort Study. Biomed Res Int 2020;2020:9108216. [PMID: 33029529 DOI: 10.1155/2020/9108216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Dong S, Qian L, Cheng Z, Chen C, Wang K, Hu S, Zhang X, Wu T. Lactate and Myocadiac Energy Metabolism. Front Physiol 2021;12:715081. [PMID: 34483967 DOI: 10.3389/fphys.2021.715081] [Reference Citation Analysis]
8 Jannapureddy S, Sharma M, Yepuri G, Schmidt AM, Ramasamy R. Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications. Front Endocrinol (Lausanne) 2021;12:636267. [PMID: 33776930 DOI: 10.3389/fendo.2021.636267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kulkarni CA, Nadtochiy SM, Kennedy L, Zhang J, Chhim S, Alwaseem H, Murphy E, Fu D, Brookes PS. ALKBH7 mediates necrosis via rewiring of glyoxal metabolism. Elife 2020;9:e58573. [PMID: 32795389 DOI: 10.7554/eLife.58573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
10 Jiang L, Shi K, Guo YK, Ren Y, Li ZL, Xia CC, Li L, Liu X, Xie LJ, Gao Y, Shen MT, Deng MY, Yang ZG. The additive effects of obesity on myocardial microcirculation in diabetic individuals: a cardiac magnetic resonance first-pass perfusion study. Cardiovasc Diabetol 2020;19:52. [PMID: 32375795 DOI: 10.1186/s12933-020-01028-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Gollmer J, Zirlik A, Bugger H. Mitochondrial Mechanisms in Diabetic Cardiomyopathy. Diabetes Metab J 2020;44:33-53. [PMID: 32097997 DOI: 10.4093/dmj.2019.0185] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 25.0] [Reference Citation Analysis]
12 Evans M, Morgan AR, Yousef Z, Ellis G, Dashora U, Patel DC, Brown P, Hanif W, Townend JN, Kanumilli N, Moore J, Wilding JPH, Bain SC. Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs 2021;81:1243-55. [PMID: 34160822 DOI: 10.1007/s40265-021-01538-6] [Reference Citation Analysis]
13 Gong W, Zhang S, Chen Y, Shen J, Zheng Y, Liu X, Zhu M, Meng G. Protective role of hydrogen sulfide against diabetic cardiomyopathy via alleviating necroptosis. Free Radical Biology and Medicine 2022;181:29-42. [DOI: 10.1016/j.freeradbiomed.2022.01.028] [Reference Citation Analysis]
14 Marchini GS, Cestari IN, Salemi VMC, Irigoyen MC, Arnold A, Kakoi A, Rocon C, Aiello VD, Cestari IA. Early changes in myocyte contractility and cardiac function in streptozotocin-induced type 1 diabetes in rats. PLoS One 2020;15:e0237305. [PMID: 32822421 DOI: 10.1371/journal.pone.0237305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Zhang M, Sui W, Xing Y, Cheng J, Cheng C, Xue F, Zhang J, Wang X, Zhang C, Hao P, Zhang Y. Angiotensin IV attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy, apoptosis and fibrosis. Theranostics 2021;11:8624-39. [PMID: 34522203 DOI: 10.7150/thno.48561] [Reference Citation Analysis]
16 Frangogiannis NG. The Extracellular Matrix in Ischemic and Nonischemic Heart Failure. Circ Res. 2019;125:117-146. [PMID: 31219741 DOI: 10.1161/circresaha.119.311148] [Cited by in Crossref: 97] [Cited by in F6Publishing: 74] [Article Influence: 32.3] [Reference Citation Analysis]
17 Paramesha B, Anwar MS, Meghwani H, Maulik SK, Arava SK, Banerjee SK. Sirt1 and Sirt3 Activation Improved Cardiac Function of Diabetic Rats via Modulation of Mitochondrial Function. Antioxidants (Basel) 2021;10:338. [PMID: 33668369 DOI: 10.3390/antiox10030338] [Reference Citation Analysis]
18 Li Z, Zhao H, Wang J. Metabolism and Chronic Inflammation: The Links Between Chronic Heart Failure and Comorbidities. Front Cardiovasc Med 2021;8:650278. [PMID: 34026868 DOI: 10.3389/fcvm.2021.650278] [Reference Citation Analysis]
19 Jubaidi FF, Zainalabidin S, Taib IS, Hamid ZA, Budin SB. The Potential Role of Flavonoids in Ameliorating Diabetic Cardiomyopathy via Alleviation of Cardiac Oxidative Stress, Inflammation and Apoptosis. Int J Mol Sci 2021;22:5094. [PMID: 34065781 DOI: 10.3390/ijms22105094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Liu SP, Shibu MA, Tsai FJ, Hsu YM, Tsai CH, Chung JG, Yang JS, Tang CH, Wang S, Li Q, Huang CY. Tetramethylpyrazine reverses high-glucose induced hypoxic effects by negatively regulating HIF-1α induced BNIP3 expression to ameliorate H9c2 cardiomyoblast apoptosis. Nutr Metab (Lond) 2020;17:12. [PMID: 32021640 DOI: 10.1186/s12986-020-0432-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
21 Schwartz B, Pierce C, Vasan RS, Schou M, Ibrahim M, Monahan K, Lyass A, Malmborg M, Gislason GH, Køber L, Torp-Pedersen C, Andersson C. Lifetime Risk of Heart Failure and Trends in Incidence Rates Among Individuals With Type 2 Diabetes Between 1995 and 2018. J Am Heart Assoc 2021;10:e021230. [PMID: 34713706 DOI: 10.1161/JAHA.121.021230] [Reference Citation Analysis]
22 Chen Y, Qie X, Quan W, Zeng M, Qin F, Chen J, Adhikari B, He Z. Omnifarious fruit polyphenols: an omnipotent strategy to prevent and intervene diabetes and related complication? Crit Rev Food Sci Nutr 2021;:1-37. [PMID: 34792409 DOI: 10.1080/10408398.2021.2000932] [Reference Citation Analysis]
23 Aamir K, Khan HU, Hossain CF, Afrin MR, Jusuf PR, Waheed I, Sethi G, Arya A. Arjunolic acid downregulates elevated blood sugar and pro-inflammatory cytokines in streptozotocin (STZ)-nicotinamide induced type 2 diabetic rats. Life Sci 2022;289:120232. [PMID: 34919901 DOI: 10.1016/j.lfs.2021.120232] [Reference Citation Analysis]
24 Yin Q, Li Z, Lu S, Busardò F. Knockdown of ILK Alleviates High Glucose-Induced Damage of H9C2 Cells through TLR4/MyD88/NF-κB Pathway. Disease Markers 2022;2022:1-9. [DOI: 10.1155/2022/6205190] [Reference Citation Analysis]
25 Gibb AA, Murray EK, Eaton DM, Huynh AT, Tomar D, Garbincius JF, Kolmetzky DW, Berretta RM, Wallner M, Houser SR, Elrod JW. Molecular Signature of HFpEF: Systems Biology in a Cardiac-Centric Large Animal Model. JACC Basic Transl Sci 2021;6:650-72. [PMID: 34466752 DOI: 10.1016/j.jacbts.2021.07.004] [Reference Citation Analysis]
26 Hu Q, Zhang H, Gutiérrez Cortés N, Wu D, Wang P, Zhang J, Mattison JA, Smith E, Bettcher LF, Wang M, Lakatta EG, Sheu SS, Wang W. Increased Drp1 Acetylation by Lipid Overload Induces Cardiomyocyte Death and Heart Dysfunction. Circ Res 2020;126:456-70. [PMID: 31896304 DOI: 10.1161/CIRCRESAHA.119.315252] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 13.0] [Reference Citation Analysis]
27 Wende AR, Schell JC, Ha CM, Pepin ME, Khalimonchuk O, Schwertz H, Pereira RO, Brahma MK, Tuinei J, Contreras-Ferrat A, Wang L, Andrizzi CA, Olsen CD, Bradley WE, Dell'Italia LJ, Dillmann WH, Litwin SE, Abel ED. Maintaining Myocardial Glucose Utilization in Diabetic Cardiomyopathy Accelerates Mitochondrial Dysfunction. Diabetes 2020;69:2094-111. [PMID: 32366681 DOI: 10.2337/db19-1057] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
28 Ramugounder R; Molecular and Cellular Research Unit, Kongunadu Arts and Science College, Bharathiar University, India. . AIMS Molecular Science 2020;7:349-73. [DOI: 10.3934/molsci.2020017] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Koliaki C, Katsilambros N. Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologist's Perspective: Lessons Learned from Cardiovascular Outcome Trials. Int J Environ Res Public Health 2019;17:E155. [PMID: 31878281 DOI: 10.3390/ijerph17010155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020;17:585-607. [PMID: 32080423 DOI: 10.1038/s41569-020-0339-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 33.5] [Reference Citation Analysis]
31 Wang A, Li Z, Zhuo S, Gao F, Zhang H, Zhang Z, Ren G, Ma X. Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology. Front Cardiovasc Med 2022;9:857952. [DOI: 10.3389/fcvm.2022.857952] [Reference Citation Analysis]
32 Hirose K, Nakanishi K, Daimon M, Sawada N, Yoshida Y, Iwama K, Yamamoto Y, Ishiwata J, Hirokawa M, Koyama K, Nakao T, Morita H, Di Tullio MR, Homma S, Komuro I. Impact of insulin resistance on subclinical left ventricular dysfunction in normal weight and overweight/obese japanese subjects in a general community. Cardiovasc Diabetol 2021;20:22. [PMID: 33478525 DOI: 10.1186/s12933-020-01201-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Fudim M, Devaraj S, Chukwurah M, Ajam T, Razaghizad A, Salah HM, Sharma A, Savarese G, Vaduganathan M, Kamalesh M. Prognosis for patients with heart failure and reduced ejection fraction with and without diabetes: A 7 year nationwide veteran administration analysis. Int J Cardiol 2022;346:30-4. [PMID: 34800593 DOI: 10.1016/j.ijcard.2021.11.032] [Reference Citation Analysis]
34 Grigorescu ED, Lacatusu CM, Floria M, Mihai BM, Cretu I, Sorodoc L. Left Ventricular Diastolic Dysfunction in Type 2 Diabetes-Progress and Perspectives. Diagnostics (Basel) 2019;9:E121. [PMID: 31533216 DOI: 10.3390/diagnostics9030121] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
35 Nieuwenhuis S, Okkersen K, Widomska J, Blom P, 't Hoen PAC, van Engelen B, Glennon JC. Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1. Front Neurol 2019;10:1229. [PMID: 31849810 DOI: 10.3389/fneur.2019.01229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
36 Lebedev DA, Lyasnikova EA, Vasilyeva AA, Vasilyeva EY, Babenko AY, Shlyakhto EV. Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes. Russ J Cardiol 2020;25:3967. [DOI: 10.15829/1560-4071-2020-3967] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
37 Henson SM, Aksentijevic D. Senescence and Type 2 Diabetic Cardiomyopathy: How Young Can You Die of Old Age? Front Pharmacol 2021;12:716517. [PMID: 34690759 DOI: 10.3389/fphar.2021.716517] [Reference Citation Analysis]
38 Liu Y, Wu S, Zhao Q, Yang Z, Yan X, Li C, Zha W, Yu W. Trehalose Ameliorates Diabetic Cardiomyopathy: Role of the PK2/PKR Pathway. Oxid Med Cell Longev 2021;2021:6779559. [PMID: 34970418 DOI: 10.1155/2021/6779559] [Reference Citation Analysis]
39 Shraim BA, Moursi MO, Benter IF, Habib AM, Akhtar S. The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications. Front Pharmacol 2021;12:701390. [PMID: 34408653 DOI: 10.3389/fphar.2021.701390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Huang S, Wang J, Men H, Tan Y, Lin Q, Gozal E, Zheng Y, Cai L. Cardiac metallothionein overexpression rescues diabetic cardiomyopathy in Akt2-knockout mice. J Cell Mol Med 2021;25:6828-40. [PMID: 34053181 DOI: 10.1111/jcmm.16687] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Diviani D, Osman H, Delaunay M, Kaiser S. The role of A-kinase anchoring proteins in cardiac oxidative stress. Biochem Soc Trans 2019;47:1341-53. [PMID: 31671182 DOI: 10.1042/BST20190228] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
42 Dai L, Xie Y, Zhang W, Zhong X, Wang M, Jiang H, He Z, Liu X, Zeng H, Wang H. Weighted Gene Co-Expression Network Analysis Identifies ANGPTL4 as a Key Regulator in Diabetic Cardiomyopathy via FAK/SIRT3/ROS Pathway in Cardiomyocyte. Front Endocrinol (Lausanne) 2021;12:705154. [PMID: 34616362 DOI: 10.3389/fendo.2021.705154] [Reference Citation Analysis]
43 Liu J, Hu X. Impact of insulin therapy on outcomes of diabetic patients with heart failure: A systematic review and meta-analysis. Diab Vasc Dis Res 2022;19:14791641221093175. [PMID: 35543342 DOI: 10.1177/14791641221093175] [Reference Citation Analysis]
44 Osundolire S, Naqvi S, Nunes AP, Lapane KL. Heart failure among US nursing home residents with diabetes mellitus. Int J Cardiol 2021:S0167-5273(21)01777-0. [PMID: 34826498 DOI: 10.1016/j.ijcard.2021.11.035] [Reference Citation Analysis]
45 Chen HF, Chang YH, Lo HJ, Isfandiari MA, Martini S, Hou WH, Li CY. Incidence of idiopathic cardiomyopathy in patients with type 2 diabetes in Taiwan: age, sex, and urbanization status-stratified analysis. Cardiovasc Diabetol 2020;19:177. [PMID: 33054769 DOI: 10.1186/s12933-020-01144-y] [Reference Citation Analysis]
46 Ling S, Xu JW. NETosis as a Pathogenic Factor for Heart Failure. Oxid Med Cell Longev 2021;2021:6687096. [PMID: 33680285 DOI: 10.1155/2021/6687096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Zaveri MP, Perry JC, Schuetz TM, Memon MD, Faiz S, Cancarevic I. Diabetic Cardiomyopathy as a Clinical Entity: Is It a Myth? Cureus. 2020;12:e11100. [PMID: 33240696 DOI: 10.7759/cureus.11100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Jordhani M, Seiti J, Barrios V. Clinical and echocardiographic characteristics in patients with heart failure and type 2 diabetes. Future Cardiol 2022. [PMID: 35506465 DOI: 10.2217/fca-2022-0006] [Reference Citation Analysis]
49 Mai Z, Li H, Chen G, Chen E, Liu L, Lun Z, Lai W, Zhou C, Yu S, Liu J, Chen S, Chen J, Liu Y. A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology. Cardiovasc Drugs Ther 2021. [PMID: 34028657 DOI: 10.1007/s10557-021-07186-y] [Reference Citation Analysis]
50 Tremamunno S, De Vita A, Villano A, Melita V, Ingrasciotta G, Ruscio E, Filice M, Bisignani A, Ravenna SE, Tartaglione L, Rizzo GE, Di Leo M, Felici T, Pitocco D, Lanza GA. Relation of endothelial and cardiac autonomic function with left ventricle diastolic function in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2021;:e3484. [PMID: 34240534 DOI: 10.1002/dmrr.3484] [Reference Citation Analysis]
51 Lebedev DA, Lyasnikova EA, Vasilyeva EY, Babenko AY, Shlyakhto EV. Type 2 Diabetes Mellitus and Chronic Heart Failure with Midrange and Preserved Ejection Fraction: A Focus on Serum Biomarkers of Fibrosis. J Diabetes Res 2020;2020:6976153. [PMID: 33224989 DOI: 10.1155/2020/6976153] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
52 Lin J, Wang F, Jiang G, Zhang T, Zhang J, He Q, Fan Y. LXR activation ameliorates high glucose stress-induced aberrant mitochondrial dynamics via downregulation of Calpain1 expression in H9c2 cardiomyoblasts. Biochem Biophys Res Commun 2022;614:145-52. [PMID: 35597151 DOI: 10.1016/j.bbrc.2022.05.025] [Reference Citation Analysis]
53 Patoulias D, Papadopoulos C, Karagiannis A, Doumas M. Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. Am J Cardiol 2022:S0002-9149(21)01259-5. [PMID: 35045931 DOI: 10.1016/j.amjcard.2021.12.040] [Reference Citation Analysis]
54 Bravo-Sánchez E, Peña-Montes D, Sánchez-Duarte S, Saavedra-Molina A, Sánchez-Duarte E, Montoya-Pérez R. Effects of Apocynin on Heart Muscle Oxidative Stress of Rats with Experimental Diabetes: Implications for Mitochondria. Antioxidants (Basel) 2021;10:335. [PMID: 33668280 DOI: 10.3390/antiox10030335] [Reference Citation Analysis]
55 Su BC, Hsu PL, Mo FE. CCN1 triggers adaptive autophagy in cardiomyocytes to curb its apoptotic activities. J Cell Commun Signal 2020;14:93-100. [PMID: 31659628 DOI: 10.1007/s12079-019-00534-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
56 Dziopa K, Asselbergs FW, Gratton J, Chaturvedi N, Schmidt AF. Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings. Diabetologia 2022. [PMID: 35032176 DOI: 10.1007/s00125-021-05640-y] [Reference Citation Analysis]
57 Wang SY, Zou C, Liu XF, Yan YJ, Gu SZ, Li X. Vascular endothelial growth factor ameliorated palmitate-induced cardiomyocyte injury via JNK pathway. In Vitro Cell Dev Biol Anim 2021;57:886-95. [PMID: 34791626 DOI: 10.1007/s11626-021-00616-z] [Reference Citation Analysis]
58 Zheng DM, An ZN, Ge MH, Wei DZ, Jiang DW, Xing XJ, Shen XL, Liu C. Medium & long-chain acylcarnitine's relation to lipid metabolism as potential predictors for diabetic cardiomyopathy: a metabolomic study. Lipids Health Dis 2021;20:151. [PMID: 34727932 DOI: 10.1186/s12944-021-01576-9] [Reference Citation Analysis]
59 Lisco G, Giagulli VA, Iovino M, Zupo R, Guastamacchia E, De Pergola G, Iacoviello M, Triggiani V. Endocrine system dysfunction and chronic heart failure: a clinical perspective. Endocrine 2021. [PMID: 34713389 DOI: 10.1007/s12020-021-02912-w] [Reference Citation Analysis]
60 Sun Y, Ding S. NLRP3 Inflammasome in Diabetic Cardiomyopathy and Exercise Intervention. Int J Mol Sci 2021;22:13228. [PMID: 34948026 DOI: 10.3390/ijms222413228] [Reference Citation Analysis]
61 Choi RH, Tatum SM, Symons JD, Summers SA, Holland WL. Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat Rev Cardiol 2021. [PMID: 33772258 DOI: 10.1038/s41569-021-00536-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Quagliariello V, De Laurentiis M, Cocco S, Rea G, Bonelli A, Caronna A, Lombari MC, Conforti G, Berretta M, Botti G, Maurea N. NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells. Int J Mol Sci 2020;21:E7802. [PMID: 33096896 DOI: 10.3390/ijms21207802] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
63 Infante M, Padilla N, Alejandro R, Caprio M, Della-morte D, Fabbri A, Ricordi C. Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents. Medicina 2022;58:571. [DOI: 10.3390/medicina58050571] [Reference Citation Analysis]
64 Zhou Y, Wang M, Wang S, Li N, Zhang S, Tang S, Shi Q, Zhao Y, Li J, Zeng Y, Song H, Tian H, Li S, Li S. Diabetes in Patients With Heart Failure With Reduced Ejection Fraction During Hospitalization: A Retrospective Observational Study. Front Endocrinol (Lausanne) 2021;12:727188. [PMID: 34456878 DOI: 10.3389/fendo.2021.727188] [Reference Citation Analysis]
65 Lu L, Ma J, Liu Y, Shao Y, Xiong X, Duan W, Gao E, Yang Q, Chen S, Yang J, Ren J, Zheng Q, Liu J. FSTL1-USP10-Notch1 Signaling Axis Protects Against Cardiac Dysfunction Through Inhibition of Myocardial Fibrosis in Diabetic Mice. Front Cell Dev Biol 2021;9:757068. [DOI: 10.3389/fcell.2021.757068] [Reference Citation Analysis]
66 Chen C, Peng H, Li M, Lu X, Huang M, Zeng Y, Dong G. Patients With Type 2 Diabetes Mellitus and Heart Failure Benefit More From Sodium-Glucose Cotransporter 2 Inhibitor: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:664533. [PMID: 34759887 DOI: 10.3389/fendo.2021.664533] [Reference Citation Analysis]
67 Bassyouni F, Tarek M, Salama A, Ibrahim B, Salah El Dine S, Yassin N, Hassanein A, Moharam M, Abdel-Rehim M. Promising Antidiabetic and Antimicrobial Agents Based on Fused Pyrimidine Derivatives: Molecular Modeling and Biological Evaluation with Histopathological Effect. Molecules 2021;26:2370. [PMID: 33921827 DOI: 10.3390/molecules26082370] [Reference Citation Analysis]
68 Tian CJ, Zhang JH, Liu J, Ma Z, Zhen Z. Ryanodine receptor and immune-related molecules in diabetic cardiomyopathy. ESC Heart Fail 2021;8:2637-46. [PMID: 34013670 DOI: 10.1002/ehf2.13431] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
69 Ke X, Lin Z, Ye Z, Leng M, Chen B, Jiang C, Jiang X, Li G. Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy. Front Endocrinol (Lausanne) 2021;12:679655. [PMID: 34367065 DOI: 10.3389/fendo.2021.679655] [Reference Citation Analysis]
70 Mashayekhi-Sardoo H, Mohammadpour AH, Mehri S, Kamali H, Sahebkar A, Imenshahidi M. Diabetes mellitus aggravates ranolazine-induced ECG changes in rats. J Interv Card Electrophysiol 2021. [PMID: 34155553 DOI: 10.1007/s10840-021-01016-9] [Reference Citation Analysis]
71 Singhal R, Hechanova LA. SGLT2 Inhibitors: Benefits for CKD and Cardiovascular Disease in Type 2 Diabetes. Curr Cardiol Rep 2022. [PMID: 35147891 DOI: 10.1007/s11886-022-01637-0] [Reference Citation Analysis]
72 Wingard MC, Frasier CR, Singh M, Singh K. Heart failure and diabetes: role of ATM. Curr Opin Pharmacol 2020;54:27-35. [PMID: 32745970 DOI: 10.1016/j.coph.2020.06.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
73 Thai PN, Miller CV, King MT, Schaefer S, Veech RL, Chiamvimonvat N, Bers DM, Dedkova EN. Ketone Ester D-β-Hydroxybutyrate-(R)-1,3 Butanediol Prevents Decline in Cardiac Function in Type 2 Diabetic Mice. J Am Heart Assoc 2021;10:e020729. [PMID: 34583524 DOI: 10.1161/JAHA.120.020729] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Njoroge JN, Teerlink JR. Pathophysiology and Therapeutic Approaches to Acute Decompensated Heart Failure. Circ Res 2021;128:1468-86. [PMID: 33983837 DOI: 10.1161/CIRCRESAHA.121.318186] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Cappetta D, De Angelis A, Bellocchio G, Telesca M, Cianflone E, Torella D, Rossi F, Urbanek K, Berrino L. Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey. Front Cardiovasc Med 2021;8:810791. [PMID: 35004918 DOI: 10.3389/fcvm.2021.810791] [Reference Citation Analysis]
76 Pepin ME, Ha CM, Potter LA, Bakshi S, Barchue JP, Haj Asaad A, Pogwizd SM, Pamboukian SV, Hidalgo BA, Vickers SM, Wende AR. Racial and socioeconomic disparity associates with differences in cardiac DNA methylation among men with end-stage heart failure. Am J Physiol Heart Circ Physiol 2021;320:H2066-79. [PMID: 33769919 DOI: 10.1152/ajpheart.00036.2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Nana M, Morgan H, Bondugulapati LNR. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future. Heart Fail Rev 2021;26:953-60. [PMID: 32020487 DOI: 10.1007/s10741-020-09925-z] [Reference Citation Analysis]
78 Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology 2022. [DOI: 10.1016/j.jacc.2021.12.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Yandrapalli S, Malik AH, Namrata F, Pemmasani G, Bandyopadhyay D, Vallabhajosyula S, Aronow WS, Frishman WH, Jain D, Cooper HA, Panza JA. Influence of diabetes mellitus interactions with cardiovascular risk factors on post-myocardial infarction heart failure hospitalizations. Int J Cardiol 2021:S0167-5273(21)01976-8. [PMID: 34864085 DOI: 10.1016/j.ijcard.2021.11.086] [Reference Citation Analysis]
80 Wei J, Zhao Y, Liang H, Du W, Wang L. Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy. Acta Pharmaceutica Sinica B 2022;12:1-17. [DOI: 10.1016/j.apsb.2021.08.026] [Reference Citation Analysis]
81 Montada-Atin T, Prasad GVR. Recent advances in new-onset diabetes mellitus after kidney transplantation. World J Diabetes 2021; 12(5): 541-555 [PMID: 33995843 DOI: 10.4239/wjd.v12.i5.541] [Reference Citation Analysis]
82 Cividini F, Scott BT, Suarez J, Casteel DE, Heinz S, Dai A, Diemer T, Suarez JA, Benner CW, Ghassemian M, Dillmann WH. Ncor2/PPARα-Dependent Upregulation of MCUb in the Type 2 Diabetic Heart Impacts Cardiac Metabolic Flexibility and Function. Diabetes 2021;70:665-79. [PMID: 33303689 DOI: 10.2337/db20-0779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Sinamaw D, Getnet M, Abdulkadir M, Abebaw K, Ebrahim M, Diress M, Akalu Y, Ambelu A, Dagnew B. Patterns and associated factors of electrocardiographic abnormality among type 2 diabetic patients in Amhara National Regional State Referral Hospitals, Ethiopia: a multicenter institution-based cross-sectional study. BMC Cardiovasc Disord 2022;22:230. [PMID: 35590246 DOI: 10.1186/s12872-022-02661-2] [Reference Citation Analysis]
84 Deng J. Research progress on the molecular mechanism of coronary microvascular endothelial cell dysfunction. Int J Cardiol Heart Vasc 2021;34:100777. [PMID: 33912653 DOI: 10.1016/j.ijcha.2021.100777] [Reference Citation Analysis]
85 Severino P, D'Amato A, Prosperi S, Costi B, Angotti D, Birtolo LI, Chimenti C, Lavalle C, Maestrini V, Mancone M, Fedele F. Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient. Heart Fail Rev 2021. [PMID: 34654997 DOI: 10.1007/s10741-021-10170-1] [Reference Citation Analysis]
86 Mori Y, Matsui T, Hirano T, Yamagishi SI. GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease-A Systematic Review. Int J Mol Sci 2020;21:E1509. [PMID: 32098413 DOI: 10.3390/ijms21041509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
87 Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac Energy Metabolism in Heart Failure. Circ Res 2021;128:1487-513. [PMID: 33983836 DOI: 10.1161/CIRCRESAHA.121.318241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
88 Tilinca MC, Tiuca RA, Tilea I, Varga A. The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients. J Pers Med 2021;11:1249. [PMID: 34945721 DOI: 10.3390/jpm11121249] [Reference Citation Analysis]
89 Kaur N, Guan Y, Raja R, Ruiz-Velasco A, Liu W. Mechanisms and Therapeutic Prospects of Diabetic Cardiomyopathy Through the Inflammatory Response. Front Physiol 2021;12:694864. [PMID: 34234695 DOI: 10.3389/fphys.2021.694864] [Reference Citation Analysis]
90 Fernandez-Caggiano M, Eaton P. Heart failure-emerging roles for the mitochondrial pyruvate carrier. Cell Death Differ 2021;28:1149-58. [PMID: 33473180 DOI: 10.1038/s41418-020-00729-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Ceriello A, Catrinoiu D, Chandramouli C, Cosentino F, Dombrowsky AC, Itzhak B, Lalic NM, Prattichizzo F, Schnell O, Seferović PM, Valensi P, Standl E; D&CVD EASD Study Group. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovasc Diabetol 2021;20:218. [PMID: 34740359 DOI: 10.1186/s12933-021-01408-1] [Reference Citation Analysis]
92 Najjar RS, Feresin RG. Protective Role of Polyphenols in Heart Failure: Molecular Targets and Cellular Mechanisms Underlying Their Therapeutic Potential. Int J Mol Sci 2021;22:1668. [PMID: 33562294 DOI: 10.3390/ijms22041668] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Klen J, Dolžan V. Treatment Response to SGLT2 Inhibitors: From Clinical Characteristics to Genetic Variations. Int J Mol Sci 2021;22:9800. [PMID: 34575958 DOI: 10.3390/ijms22189800] [Reference Citation Analysis]
94 Juraschek SP, Wang D, Mcevoy JW, Harrap S, Harris K, Mancia G, Marre M, Neal B, Patel A, Poulter NR, Williams B, Chalmers J, Woodward M, Selvin E. Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE. International Journal of Cardiology 2022. [DOI: 10.1016/j.ijcard.2022.04.044] [Reference Citation Analysis]
95 Pitso L, Mofokeng TRP, Nel R. Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central South Africa. BMC Endocr Disord 2021;21:159. [PMID: 34365977 DOI: 10.1186/s12902-021-00813-7] [Reference Citation Analysis]
96 Teshnisi MA, Vakilian F, Zirak N, Sedaghat A, Hoseini Khah SHR, Mohammadpoor AH, Azmonfar V, Keshtan FG, Rohani M, Bagheri R, Ardehali A. Prognosis of heart transplant patients in Mashhad University of Medical Sciences. Kardiochir Torakochirurgia Pol 2020;17:33-8. [PMID: 32728361 DOI: 10.5114/kitp.2020.94189] [Reference Citation Analysis]
97 Dhalla NS, Shah AK, Tappia PS. Role of Oxidative Stress in Metabolic and Subcellular Abnormalities in Diabetic Cardiomyopathy. Int J Mol Sci 2020;21:E2413. [PMID: 32244448 DOI: 10.3390/ijms21072413] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
98 Huo JY, Jiang WY, Zhang SG, Lyu YT, Geng J, Chen M, Chen YY, Jiang ZX, Shan QJ. Renal denervation ameliorates cardiac metabolic remodeling in diabetic cardiomyopathy rats by suppressing renal SGLT2 expression. Lab Invest 2021. [PMID: 34775493 DOI: 10.1038/s41374-021-00696-1] [Reference Citation Analysis]
99 Ren BC, Zhang YF, Liu SS, Cheng XJ, Yang X, Cui XG, Zhao XR, Zhao H, Hao MF, Li MD, Tie YY, Qu L, Li XY. Curcumin alleviates oxidative stress and inhibits apoptosis in diabetic cardiomyopathy via Sirt1-Foxo1 and PI3K-Akt signalling pathways. J Cell Mol Med 2020;24:12355-67. [PMID: 32961025 DOI: 10.1111/jcmm.15725] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
100 Radlinger B, Hornsteiner F, Folie S, Salvenmoser W, Haubner BJ, Schuetz T, Haas S, Ress C, Adolph TE, Salzmann K, Weiss B, Tilg H, Kaser S. Cardioprotective effects of short-term empagliflozin treatment in db/db mice. Sci Rep 2020;10:19686. [PMID: 33184414 DOI: 10.1038/s41598-020-76698-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Gollmer J, Zirlik A, Bugger H. Established and Emerging Mechanisms of Diabetic Cardiomyopathy. J Lipid Atheroscler 2019;8:26-47. [PMID: 32821697 DOI: 10.12997/jla.2019.8.1.26] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]